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A primary means for the augmentation of cognitive brain functions is “pharmacological
cognitive enhancement” (PCE). The term usually refers to the off-label use of medical
substances to improve mental performance in healthy individuals. With the final aim to
advance the normative debate taking place on that topic, several empirical studies have
been conducted to assess the attitudes toward PCE in the public, i.e., in groups outside
of the academic debate. In this review, we provide an overview of the 40 empirical
studies published so far, reporting both their methodology and results. Overall, we find
that several concerns about the use of PCE are prevalent in the public. These concerns
largely match those discussed in the normative academic debate. We present our
findings structured around the three most common concerns: medical safety, coercion,
and fairness. Fairness is divided into three subthemes: equality of opportunity, honesty,
and authenticity. Attitudes regarding some concerns are coherent across studies (e.g.,
coercion), whereas for others we find mixed results (e.g., authenticity). Moreover, we
find differences in how specific groups—such as users, nonusers, students, parents,
and health care providers—perceive PCE: a coherent finding is that nonusers display
more concerns regarding medical safety and fairness than users. We discuss potential
psychological explanations for these differences.
Keywords: cognitive enhancement, neuroenhancement, brain function augmentation, medical safety, coercion,
fairness, authenticity, smart drugs
INTRODUCTION
Brain enhancement is a topic of huge interest in themedia and the
academic literature. An often discussed form of brain enhance-
ment is pharmacological cognitive enhancement (PCE) which usu-
ally refers to the use of certain prescription substances. Schermer
et al. (2009) define these sorts of enhancements as “pharmaco-
logical interventions that are intended to improve certain mental
functions and that go beyond currently accepted medical indi-
cations” (p. 77). PCE is not only a topic that is debated in
academia—mainly in neuroscience, law, and ethics—but also a
reality: several surveys show that students, but also other groups
such as academics and surgeons, use substances to enhance
their cognitive performance (e.g., Maher, 2008; Smith and Farah,
2011; Franke et al., 2013). Examples of seemingly common
pharmacological enhancers are methylphenidate (e.g., Ritalin®),
mixed amphetamine salts (e.g., Aderall®), and modafinil (e.g.,
Provigil®). Originally, the first two were developed as treatment
for Attention Deficit Hyperactivity Disorder and the latter as
treatment for Narcolepsy, but now they are being used to enhance
performance in healthy individuals.
Although there are considerable intra- and interpersonal dif-
ferences in the effects of these substances (e.g., Husain andMehta,
2011; Van Der Schaaf et al., 2013), average effects have been
reported. In their overview of findings and meta-analysis of the
effects of methylphenidate and modafinil in healthy individu-
als, Repantis et al. (2010) assessed mood, motivation and four
categories of cognitive processes: wakefulness, attention and vig-
ilance, memory and learning, and executive functions and infor-
mation processing. The available data about methylphenidate did
not provide enough information to draw a firm conclusion about
the effects of methylphenidate on enhancing or maintaining per-
formance, although evidence for a positive effect on memory was
found. An enhancing effect on attention was not verified, con-
flicting with the goal of increasing concentration and alertness
that users of enhancement substances often have (Teter et al.,
2005). The aggregated findings of potential enhancing effects of
modafinil indicate that it improves attention for well-rested indi-
viduals. Furthermore, it helps in maintaining a higher degree
of wakefulness, memory and executive functions over a period
of sleep deprivation (Repantis et al., 2010). The authors suggest
that these effects led to a growing popularity of modafinil, and
strongly recommend a public debate on the ethics of the use of
PCE which takes this into account. However, other reviews did
not find any effect or even suggested that the non-cognitive effects
of the substances, e.g., on confidence and motivation, might be
responsible for enhanced performance (Farah et al., 2014).
In the normative debate about whether or not PCE is to be
endorsed, certain concerns about its use are often raised and have
been discussed by several authors (e.g., Farah et al., 2004; Bostrom
and Sandberg, 2009; Schermer et al., 2009; Hyman, 2011). In this
review, we focus on three concerns that are most often empha-
sized by the public, but are also discussed in the normative debate.
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First, the medical safety of the aforementioned substances has
been discussed, in particular in terms of short- or long-term side
effects. A second topic of discussion is coercion, relating to con-
cerns about the explicit and implicit pressures that can arise from
the availability of PCE, forcing people to use these substances to
be able to compete, for example at the workplace or in school.
The third concern relates to the fairness of the use of PCE. This
concern includes several subtopics such as a possible unequal dis-
tribution of access to such enhancers, their use in competitive
environments being seen as cheating, and also to what degree
performance brought about under PCE can be seen as authentic.
There are good reasons to examine the attitudes of the public
toward PCE in addition to this normative debate. In their plea
for the inclusion of public views on developments in biomedicine
and technology, Schicktanz et al. (2012) underline a view already
suggested a few years ago by Sarewitz (2010) in a column in
Nature. They propose three general arguments for the inclusion
of the public in ethical reasoning. First, views and attitudes of the
public can point to remote or emerging moral problems. Second,
empirical research can be used to examine premises about human
behavior and social consequences of actions that underlie sev-
eral applied ethical arguments. Third, research on public opinions
can increase the context-sensitivity of ethical reasoning by point-
ing out consequences of concrete decisions in social policy. They
argue that any bioethical discussion that avoids a confrontation
with public opinions “not only runs the risk of missing important
aspects, ideas, and arguments. It also arouses strong suspicion of
being indeed one-sided, biased or ideological—thus illegitimate.”
(Schicktanz et al., 2012, p. 136). Apart from the aforementioned
general arguments to include the public’s attitude in certain
bioethical discussions, specific arguments for the case of PCE are
also made. Faulmüller et al. (2013) describe how PCE, as long as
it is perceived negatively by the public, might give rise to indirect
psychological costs for users: they might be treated in ways that
damage their psychological well-being, for example by a misat-
tribution of their success to the enhancer rather than themselves,
or by dehumanization or ostracism. More insight into the pub-
lic’s view can lead to more insight into these potential indirect
psychological costs. In addition, Banjo et al. (2010) argue that
physicians are and will be “gatekeepers” in dispensing at least a
portion of PCE substances. Although there is discussion on if and
how their views might affect social policy or legal regulation on
PCE (Delaney andMartin, 2011), PCE is part of their clinical real-
ity. Therefore their views can provide specific insights that are of
importance to the general debate (Ott et al., 2012).
The current article is based on an extensive literature search.
We used two databases, Web of Science and Scopus, and included
all articles published in English between 1990 and 2014. The
search terms we used were [(“cognitive enhancer” OR “cog-
nitive enhancement” OR “pharmacological enhancement” OR
“prescription drug” OR “performance enhancing drug” OR neu-
roenhancement OR “human enhancement”) AND (view OR
perspective OR opinion OR attitude OR judgment OR motive
OR justification)] as part of the title, abstract or keyword of the
text. This search resulted in 447 articles in Web of Science and
4162 articles in Scopus. Based on a careful check of titles and
abstracts, we selected all articles that reported empirical studies
on the opinions of groups outside the normative academic debate
(such as students or physicians) on the use of PCE. We also cross-
checked the reference lists of the studies found this way to identify
additional relevant literature matching our inclusion criteria.
Moreover, we checked Google Scholar and asked colleagues pub-
lishing in this area to direct us to relevant publications. Overall,
this search resulted in 40 publications reporting qualitative or
quantitative examinations of attitudes, opinions, and views of the
general public and more often specific sub-populations toward
PCE, which we included in this review. These 40 publications are
marked with an asterisk in the reference list.
Our overarching finding is that in the public several concerns
about the use of PCE substances are prevalent: they agree on sev-
eral concerns when being asked specifically and raise concerns
themselves when being asked for their opinion. These concerns
widely match the normative debate. Hence, this review is struc-
tured around the common concerns reflected in the academic
and public debate: (1) medical safety, (2) coercion, and (3) fair-
ness. Each section in this review will be introduced with a short
description of the academic debate on the respective concern.
Then, the relevant empirical studies are reported. We also try to
pinpoint some shortcomings in the current literature and suggest
potential paths for future research. Table 1 provides an overview
of key methodological aspects of all studies reviewed, containing
information about the concerns investigated, the researchmethod
by which the data were obtained, the country where the study
took place, and the sample (occupation of participants, sample
size, sampling method, and response rate).
MEDICAL SAFETY
The normative debate about the safety of PCE usually focuses
on potential trade-offs between benefits and risks. As with all
medical procedures, there might be side effects and yet-unknown
long-term health risks with substances such as methylphenidate
or modafinil (King et al., 2006). Schermer et al. (2009) point out
that the harm-benefit ratio of PCE deserves special consideration,
as the life-improving benefits might not outweigh the potential
risks for consumers who use them for enhancement purposes,
instead of the therapeutic purposes for which the substances
were originally developed. However, Dubljevic (2013) emphasizes
the importance of analyzing different substances in a case-by-
case approach, as some entail greater health and addiction risks
than others (Kociancic et al., 2004). Several studies have exam-
ined people’s health concerns about such cognitive enhancers.
Interestingly both users and nonusers systematically overestimate
the cognitive-enhancing effects of PCE (Finger et al., 2013; Ilieva
et al., 2013), but a sharp discrepancy between their risk estima-
tions is revealed. While nonusers generally have strong concerns
regarding the safety of PCE, users show less concern.
Nonusers tend to believe that such substances are addictive,
might induce sleep disorders and may even lead to mental
health problems, which was shown in an interview study with 19
Australian students (Partridge et al., 2013). In two surveys con-
ducted on a UK university campus with a total of 357 students,
Scheske and Schnall (2012) observed that moral reservations
against PCE stem mostly from these safety concerns: the riskier
the substances, the more student respondents morally object to
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Table 1 | Overview of the empirical studies discussed in this review.
Authors Country Occupation of Sampling method Research Response Sample Concerns
participants method rate size
Aikins, 2011 USA University students Purposive sampling Semi-structured
interview
n/a 12 Safety, fairness
Asscher and
Schermer, 2013
The
Netherlands
General public Purposive sampling Focus groups n/a 37 Safety
Ball and
Wolbring, 2014
Canada Parents Purposive sampling Semi-structured
interview
n/a 12 Safety
Banjo et al., 2010 USA and
Canada
Physicians Convenience
sampling
Web-based
survey
n/a 212 Safety,
coercion,
Fairness
Bell et al., 2013 Australia University students Convenience
sampling
Interview n/a 19 Safety,
coercion
Bergström and
Lynöe, 2008
Sweden General public Random sampling Paper and pencil
questionnaire
52% 517 Safety
Physicians 39% 108
Bossaer et al.,
2013
USA University students All students at one
university invited
Web-based
survey
59.9% 372 Safety, fairness
Desantis and
Hane, 2010
USA University students Convenience
sampling
Interview n/a 175 Safety
Dodge et al.,
2012
USA University students All students at one
university invited
Web-based
survey
37% ±1200 Fairness
Dubljevic´ et al.,
2013*
Germany University students Three stage cluster
sampling
(universities,
disciplines, students)
Web-based
survey
First
wave
53.5%
5882 Fairness
Second
wave
69.1%
3486
Eickenhorst
et al., 2012
Germany University students Convenience
sampling
Web-based
survey
n/a 1218 Safety
University graduates 106
European
Citizens Panel,
2006
Belgium,
Denmark,
France,
Germany,
Greece,
Hungary,
Italy, the
Netherlands,
UK
General public Stratified random
sampling (age,
profession, gender)
Citizen’s
deliberation
n/a 126 Coercion
Fitz et al., 2013 USA and
Canada
General public Convenience
sampling, Amazon’s
Mechanical Turk
recruitment
Web-based
survey
n/a 4011 Safety,
coercion,
fairness
(Continued)
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Table 1 | Continued
Authors Country Occupation of Sampling method Research Response Sample Concerns
participants method rate size
Forlini and
Racine, 2009
Canada University students Purposive sampling Focus groups n/a 29 Coercion
Parents 21
Health care providers 15
Forlini and
Racine, 2012a
Canada University students Purposive sampling Focus groups n/a 29 Safety,
coercion,
fairness
Parents 21
Health care providers 15
Forlini and
Racine, 2012b
Canada University students Purposive sampling Focus groups n/a 29 Safety, fairness
Parents 21
Health care providers 15
Franke et al.,
2012a*
Germany High school students All students at 12
public grammar and
vocational schools,
and students of
three departments of
one university invited
Paper and pencil
questionnaire
83% 1035 Safety,
coercion,
fairness
University students 512
Franke et al.,
2012b
Germany University students Convenience
sampling
Interview n/a 22 Safety,
coercion,
fairness
Franke et al.,
2014
Germany Physicians All primary care
physicians in one
state invited
Paper and pencil
questionnaire
30.2% 832 Safety
Hotze et al., 2011 USA Physicians Random sampling Paper and pencil
questionnaire
46.6% 633 Fairness
Judson and
Langdon, 2009
USA University students All students at two
colleges invited
Paper and pencil
questionnaire
10% 333 Safety
Kudlow et al.,
2013
Canada University students All medical students
at one medical
school invited
Web-based
survey
50% 326 Safety
Maier et al.,
2013
Switzerland University students All students at three
educational
institutions invited
Web-based
survey
22.3% 6275 Coercion
Maslen et al.,
in press
Germany University students Convenience
sampling
Paper and pencil
questionnaire
n/a 80 Coercion
Mazanov et al.,
2013
Australian University students Convenience
sampling
Web-based
survey
n/a 1729 General,
fairness
Ott and
Biller-Andorno,
2013
Switzerland University students Convenience
sampling
Web-based
survey and
separate paper
and pencil
questionnaire
n/a 1765 Safety, fairness
(Continued)
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Table 1 | Continued
Authors Country Occupation of Sampling method Research Response Sample Concerns
participants method rate size
Ott et al., 2012 Switzerland Physicians Stratified random
sampling (profession,
gender, years of
training, language)
Paper and pencil
questionnaire
23.9% 379 Safety
Partridge et al.,
2012
Australia General public Random sampling Telephone
interview
31.9% 1265 General
Partridge et al.,
2013
Australia University students Convenience
sampling
Interview n/a 19 Safety
Riis et al., 2008 USA University students No information
provided
Web-based
survey
n/a 357 Fairness
Sabini and
Monterosso,
2005
USA University students Convenience
sampling
Paper and pencil
questionnaire
n/a 185 Fairness
Santoni de Sio
et al., in press
United
Kingdom
University students Convenience
sampling
Paper and pencil
questionnaire
n/a 102 Safety, fairness
Sattler et al.,
2013a*
Germany University students Three stage cluster
sampling
(universities,
disciplines, students)
Web-based
survey
87.1% 1852 Safety, fairness
(Sattler et al.,
2013b)*
Germany University teachers Three stage cluster
sampling
(universities,
disciplines,
students/teachers)
Web-based
survey
33.5% 1402 Safety
University students 69.1% 3486
Sattler et al.,
2014*
Germany University students Three stage cluster
sampling
(universities,
disciplines,
students); only
second time wave
Web-based
survey
69.1% 3486 Safety,
coercion,
fairness
Sattler and
Wiegel, 2013*
Germany University students Three stage cluster
sampling
(universities,
disciplines,
students); only
second time wave
Web-based
survey
First
wave
53.5%
5882 Safety
Second
wave
69.1%
3486
Scheske and
Schnall, 2012
UK University students Convenience
sampling, two
studies - two
samples
Paper and pencil
questionnaire
n/a 50 Safety, fairness
306
Schildmann
et al., 2013
Germany University students No information
provided
Survey n/a 1026 Coercion,
fairness
(Continued)
Frontiers in Systems Neuroscience www.frontiersin.org April 2014 | Volume 8 | Article 53 | 5
Schelle et al. Attitudes toward pharmacological cognitive enhancement
Table 1 | Continued
Authors Country Occupation of Sampling method Research Response Sample Concerns
participants method rate size
Schuijff and
Brom, 2013
The
Netherlands
All Purposive sampling Focus groups n/a 38 Safety,
coercion,
fairness
Sweeney, 2010 USA University students Convenience
sampling
Paper and pencil
questionnaire
n/a 100 Safety, fairness
Convenience sampling and purposive sampling require no random selection of participants, whereas random sampling, stratified random sampling and cluster
sampling do. Purposive sampling requires obtaining a sample of people who meet a predetermined criterion, whereas convenience sampling does not. For stratified
random sampling, a population is divided in strata (subgroups) from which participants are randomly selected to make sure all strata are represented in the sample
in proportion to their prevalence in the population. Cluster sampling requires a list of clusters, e.g., disciplines in a university, from which a few clusters are randomly
chosen. Instead of randomly selecting participants from a list of potential participants, e.g., all students of the university, every member of the selected cluster is
invited to participate (Cozby, 2009).
*The authors explicitly state that N is not equal for each analysis due to missing data or specific criteria employed.
their non-medical use. Similarly, in a survey involving 102 UK
Science students, Santoni de Sio et al. (in press) found that the
concern against enhancement use that was raised most often by
respondents related to potential unintended side-effects.
A plausible consequence is that students are less willing to
engage in PCE the higher the severity and risk of the resulting
health issues are perceived to be. This was shown in two German
factorial design online surveys based on a large pool of vignettes
with a sample of 1852 students in the first study (Sattler et al.,
2013a) and 3486 students and 1402 university teachers in the sec-
ond study (Sattler et al., 2013b; these are results of the second
wave of a biannual project; also see Sattler and Wiegel, 2013 and
Dubljevic´ et al., 2013 for findings on the first and second wave,
and (Sattler et al., 2014) for other results on the second wave).
Moreover, Franke et al. (2012a) showed in an extensive paper-
and-pencil questionnaire study with a sample of 1547 German
students that the majority would consider taking PCE substances
only if their safety could be assured.
The relation between willingness to use PCE and the perceived
risk of PCE might also be an explanation for the results from a
focus group study on several human enhancement technologies
conducted with 38 Dutch participants divided into five groups
(Schuijff and Brom, 2013). (A focus group study is a qualitative
research technique in which a group of participants discuss their
opinions on a given topic.) After more information on the effects
and risks of using methylphenidate as an enhancer was provided,
fewer participants stated they would consider using the substance
for enhancement purposes than before receiving the information.
Participants in this study were not familiar with the concept of
human enhancement, in contrast to participants in most of the
other studies, and therefore might have underestimated the risks
accompanying the use of PCE. In another Dutch focus group
study with 37 participants divided into five groups, several exam-
ples of the use of medical means to fulfill non-medical wishes
were investigated. An example related to PCE, taking β-blockers
during a driving test, raised several concerns about medical risks
(Asscher and Schermer, 2013). In a semi-structured interview
study with twelve Canadian parents of either cognitively disabled
or non-disabled children, Ball andWolbring (2014) observed that
all parents unanimously agreed that medical safety has to be
insured in order to administer PCE to their children.
Sattler and Wiegel (2013) provided the first evidence on the
influence of the perceived severity of side effects and risk atti-
tudes on actual PCE use. In a large- scale online survey with
5882, in a first wave, and 3486 respondents, in a second wave, a
lower proneness to risk and an expectation of more severe drug-
related side effects were associated with more PCE use at the first
time point and increased use of PCE over a 6-months period.
However, other results in the second wave of the same project did
not show the relation between the expected severity of side effects
or risk attitudes and willingness to use PCE (Sattler et al., 2014).
The authors did, though, find in the second wave that a higher
expected likelihood of side effects decreased the willingness to use
PCE.
Other findings suggest that natural remedies are perceived
as less harmful than PCE substances, as shown in a question-
naire study involving the Swedish general public and physicians
with a sample size of 625 in total (Bergström and Lynöe, 2008).
Furthermore, people morally object more to the application of
PCE substances if they are artificial rather than natural, and
if they are taken in the form of injections rather than pills
(Scheske and Schnall, 2012). Focus group participants in the
Netherlands referred to natural remedies, placebo, and psycho-
logical treatment as alternatives to a specific example of PCE
(taking β-blockers during a driving test; Asscher and Schermer,
2013). However, these results may depend on the familiarity of
the sample with medical substances. An online survey among 326
Canadian medical students showed that there were no significant
differences between attitudes toward pharmacological or natural
supplements for cognitive enhancement (Kudlow et al., 2013).
Furthermore, 212 US American and Canadian physicians,
reported in an online survey, being less comfortable prescribing
PCE substances for non-medical use to young adults, compared
to older patients (Banjo et al., 2010). Franke et al. (2014) con-
firmed these findings in a paper and pencil questionnaire study
among 832 German physicians. In both studies, physicians wor-
ried about misuse and deemed PCE for young people to be
unnecessary. Yet, this applied less to the treatment (i.e., medical
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use) of older patients. Consistent with these findings, an exper-
imental vignette study conducted online with 4011 respondents
found that the US American and Canadian public is more toler-
ant of side effects when they can be seen as the result of necessary
therapy instead of enhancement (Fitz et al., 2013). This touches
upon a big debate in medical ethics about the distinction between
treatment and enhancement, since this is not a distinction based
on biological facts, but, rather, reflecting subjective valuation
(Parens, 1998; Daniels, 2000; Hyman, 2011). This is also reflected
in a survey by Ott et al. (2012), who concluded that subjective
suffering is taken into account as a criterion for disease. From
the respondents, 379 Swiss general practitioners and psychia-
trists, 88% reported being influenced by the degree of subjective
suffering in prescribing an enhancer in four different scenarios.
When asked if they would prescribe a PCE substance if a stu-
dent requested a prescription to stay awake to study more, only
15% confirmed without any doubt, although 54% would pre-
scribe if there were no therapeutic alternative. Around half of the
respondents reported being confronted in their practice with such
requests for prescriptions.
In contrast to these consistent findings on nonusers, users of
PCE differ in their estimation of the safety of PCE substances.
In an online survey with 1324 German students, users tended
to rate the health consequences of PCE as less dangerous than
nonusers did (Eickenhorst et al., 2012). This could be explained
by users’ higher ratings of willingness to take risks, found in a
large-scale online survey involving 1765 Swiss students (Ott and
Biller-Andorno, 2013). Moreover, fewer individuals (63.9%) from
this latter survey’s “user group” of 108 students reported worry-
ing about side effects than individuals from the “nonuser group”
of 1689 students (81.9%). Similarly, in a semi-structured inter-
view study with 12 US American students who were illicitly or
licitly using PCE, most participants believed that the benefits
of PCE outweighed the potential negative side effects (Aikins,
2011). Another study with 333 US American students revealed
that students who were illicitly using PCE had even more pos-
itive attitudes to the use of PCE with regard to medical safety
issues compared to licit users (Judson and Langdon, 2009). In
another interview study with 22 German students who used
both caffeine and PCE, participants saw differences between the
two forms of enhancement: in particular they estimated both
the desired effects and the negative side effects as more pro-
nounced in the case of PCE (Franke et al., 2012b). Also, Sweeney
(2010) presents in her thesis results of a campus survey with a
sample of 100 US American students, which demonstrate that
students who are illicitly using cognitive enhancers seem to be
more likely than nonusers to believe that the substances are
harmless.
The aforementioned findings concerning differences between
users and nonusers in their estimation of risks and harmful-
ness might also explain the large difference between the attitudes
of users and nonusers found in other studies. A study on atti-
tudes toward the acceptableness of PCE amongst 1265 members
of the general public in Australia found that respondents who
were familiar with PCE—either by using it themselves or by
knowing somebody who used PCE—were twice as likely to find
PCE acceptable than respondents who were not familiar with it
(Partridge et al., 2012). Also users of PCE among a group of
Canadian medical students tended to have more favorable atti-
tudes toward PCE than nonusers (Kudlow et al., 2013). Lastly, a
survey of 1729 students from Australian universities revealed dif-
ferences in attitudes between users and nonusers of PCE, with
users more often finding the use of study drugs “moral” than
nonusers (Mazanov et al., 2013). The latter three studies did not
specifically present the reason why respondents had a certain atti-
tude toward PCE, and thus their opinions might not be related to
medical safety. Still, these results are in line with a common find-
ing in drug epidemiology, revealing that positive attitudes toward
a drug, in particular low perceived risk, correlate with its use (e.g.,
Bachman et al., 1998; Bavarian et al., 2013; Cabriales et al., 2013).
In addition, users justify their practice and underestimate
potential health risks for themselves and for others as shown in an
interview-based survey with 175 US American students (Desantis
and Hane, 2010). Conversely, Franke et al. (2012a) found that
users and nonusers estimate addictive risks similarly, perhaps
because there is a greater likelihood of substance dependency for
users (Kroutil et al., 2006). However, Franke et al. (2012a) did not
specifically test for PCE dependency in their study. In the above-
mentioned study by Desantis and Hane (2010), it was revealed
that users argue for the substances’ safety and downplay poten-
tial health risks by contrasting PCE to street-drugs (e.g., cocaine,
heroin, etc.) and by pointing toward their acceptance within the
medical establishment. This relates to the observation that stu-
dents who believe that they know enough in order to safely use
PCE are more likely to state that PCE is harmless (Sweeney, 2010).
The fact that users tend to estimate PCE usage as harmless might
explain why they find its application to be morally and socially
acceptable (Desantis and Hane, 2010).
Hence, there is a general discrepancy between the views of
users and nonusers with regard to the associated health risks of
PCE and its moral acceptance, with users being less concerned
than nonusers.
COERCION
The question of coercion relates to autonomy, i.e. the freedom to
decide about one’s personal life, and is a central issue in the nor-
mative debate on PCE. A main concern is that people are being
pressured or even coerced into enhancing themselves. This might
happen either indirectly in the form of peer pressure (Warren
et al., 2009), or potentially directly in certain workplaces with long
working hours and high demands on cognitive functioning, such
as in the military or in surgery (Schoomaker, 2007; Maslen et al.,
in press). While opponents of enhancement consider it a “threat
to the responsibility one bears for one’s own life” (Habermas,
2003, p. 61), proponents instead focus on its advantages. They
point out that PCE in particular entails the possibility of enhanc-
ing autonomy itself by increasing the reasoning abilities required
to engage in such autonomous decisions (Schaefer et al., 2013).
The participants in Schuijff and Brom’s (2013) focus group
study indicated implicit peer pressure and explicit demand by
employers to use human enhancement technologies to be a major
concern for them. Maslen et al. (in press) found in a survey of
80 UK students clear and strong objection against the idea that
people in professions with high responsibility, such as pilots and
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physicians, might even have a moral obligation to enhance their
performance, with only one respondent agreeing to such an obli-
gation and 44% completely disagreeing. Two other surveys among
German students found that the majority of students did not
approve of PCE in jobs with high responsibilities: in one survey
only 26% of the 1026 respondents approved of the use of PCE
in highly responsible jobs (Schildmann et al., 2013), the second
found that approximate 20% of their 1547 respondents approved
the use of PCE for individuals with high responsibility (Franke
et al., 2012a).
Forlini and Racine (2009) conducted one of the (very few)
studies investigating people’s attitudes on autonomy and coer-
cion specifically with regards to PCE, again with the use of
focus groups. Their participants, 65 Canadians assigned to one
of nine groups consisting of either students, parents, or health-
care providers, agreed that PCE should be a matter of personal
choice. This seems in line with one of the recommendations of
a “European citizens’ panel” held in 2005 and 2006, a citizens’
deliberation on brain science involving 126 individuals from nine
European countries. (A citizen’s deliberation is a form of pub-
lic participation in consultation about science, but can be less
structured than a focus group study because groups can change
during the deliberation.) One of the topics touched upon briefly
was human enhancement. The participants’ highest ranked rec-
ommendation was that people should be given the right to take
“whatever drug they want,” but enough information about the
effects and dangers should be available; however, they did not
support use of PCE in situations in which people have to pass
exams (European Citizens Panel, 2006).
Participants in Forlini and Racine’s (2009) study held the
descriptive view that users are generally deciding to take such
substances as a result of a voluntary decision. At the same time,
however, they believed that this decision can be influenced by per-
ceived social pressure or by competitive environments, such as
academia or the job market, where people are striving for suc-
cess and feel they have to perform better than average. Health
care providers amongst the participants admitted that students
who don’t take enhancersmay be disadvantaged because demands
are getting higher and PCE is becoming more prevalent. They
regarded peer pressure as an important contributing factor to the
perceived need to take cognitive enhancers. Parents, in contrast,
were aware of the pressure being put on students and conse-
quently felt worry and sadness. They feared that the use of PCE
may become a new standard.
However, peer pressure seems to be a more complex phe-
nomenon than one might assume. Sattler et al. (2014) show that
willingness to take PCE drugs does not increase when others
encourage it, but it decreases when disapproval of the use of PCE
by others rises. Furthermore, on the one hand, Forlini and Racine
(2009) observe the desire of students not to be at a disadvantage,
while on the other hand, less than 10% of 1547 German students
stated in a survey by Franke et al. (2012a) that they would use
PCE if others did so. In an online study amongst 6275 Swiss stu-
dents less than 3% agreed that other people’s use of substances
would justify the use of PCE, compared to over 66% who agreed
that increased learning would justify the use (Maier et al., 2013).
One methodological reason for these diverging findings might be
that even though a qualitative approach as used by Forlini and
Racine (2009) can reveal aspects that might stay undiscovered in
quantitative approaches like surveys, the small sample size might
limit the generalizability of the findings. Going beyond method-
ology, we might speculate that it is not other people using PCE
per se, but other people performing better, that puts pressure on
students and leads them to consider taking such substances. In
general, student participants in Forlini and Racine’s (2009) focus
groups viewed PCE as a personal lifestyle choice and emphasized
the importance of personal integrity, i.e., they accepted the use
of PCE conditional on the fact that one remains faithful to one’s
personal values. At the same time, they recognized the difficulty
of that endeavor when social pressure is high and when absti-
nence could lead to personal disadvantage. Parents of university
students, on the other hand, maintained a paternalistic view: stu-
dents should be informed about cognitive enhancement, and, as
a consequence, they should be held responsible and accountable
for the decision to engage in PCE.
Thus, people consider the role of peer pressure as problematic
and agree on the importance of deciding autonomously whether
to engage in PCE. However, since the few studies reported here
reveal mixed results, more research is needed to investigate the
topic in greater depth.
FAIRNESS
The normative debate around the fairness of PCE is perhaps the
least clearly defined. The term “fairness” seems to raise different
distinct concepts in the lay mind, and thus creates a difficulty
in comparing different studies that ask for opinions on the fair-
ness of PCE use without defining what is meant by “fair.” Overall,
fairness related concerns seem to play an important role in the
public, since they have been the second most common argument,
after unintended side effects, against the use of enhancement
raised by participants in Santoni de Sio et al.’s (in press) sur-
vey. Forlini and Racine’s (2012a also c.f. Forlini and Racine,
2009) focus-group study explored lay statements about fairness
of PCE in greater detail. They developed a model to describe
three different subthemes: they suggest that judgments of fair-
ness can (apart from external factors like legislation) be defined
by a relationship between equality of opportunity, honesty, and
authenticity. Participants who valued the equality of opportunity
described the importance of an equal distribution of opportuni-
ties to obtain PCE substances and opportunities deriving from
their use. Honesty and authenticity are both related to effort
that has to be invested to achieve a certain task. The underlying
assumption is that when high performance is achieved with less
effort—as might be the case when PCE substances are taken—
this might be less fair compared to performance that is achieved
with substantial effort. Honesty relates to the social aspect of this
assumption and reflects the effect of PCE use on other individ-
uals, for example in a competitive environment where PCE use
might be seen as cheating. Authenticity relates to the individ-
ual PCE user and questions whether his/her performance under
PCE, often seen as a situation in which effort is discounted, is
an authentic performance. It is based on the underlying belief
that putting in effort shapes the experience of an individual and
thus affects a “future” individual that does not gain the same
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experience while using PCE. Although the above separation of
concepts is too coarse to fully reflect the depth of the academic
normative debate, the concerns of the public can be grouped
around these subthemes of fairness.
EQUALITY OF OPPORTUNITY
First, we discuss equality of opportunity, the fear that inequality
in access to enhancement substances might increase inequalities
in society. Farah et al. (2004) describe how certain groups might
experience cost barriers and social barriers to access PCE. (In this
section, we do not consider concerns about restrictions of free-
dom to follow personal preferences, as these are discussed in the
previous section about coercion). Equality of opportunity is also
referred to as distributive fairness (e.g., Scheske and Schnall, 2012),
distributive justice (Farah et al., 2004), or the concern of inequal-
ity (e.g., Bostrom and Sandberg, 2009). Note that the notion of
equality of opportunity relates to a certain underlying theory of
justice (cf. Rawls, 1971), which can be contrasted, for example,
to the notion of equality of outcome. However, these underly-
ing theories are not distinguished yet in empirical research on the
public’s opinions about PCE.
Although healthcare providers, students and parents who par-
ticipated in the focus group study by Forlini and Racine (2012a)
believed that, currently, everybody who wanted could find PCE
substances one way or another, they did emphasize the impor-
tance of the value of equality of opportunity as part of their
judgment on the fairness of the use of PCE. Correspondingly, in
survey research by Sattler et al. (2013a) amongst 1852 respon-
dents, a lower score on both willingness-to-use a PCE and
moral acceptability of PCE substances was reported when judg-
ing an imaginary situation where no other students take this
PCE substance, compared to situations in which half of the
other students or all fellow students were taking the PCE sub-
stance. Possibly, they read the “no other student” situation as
one where there is inequality in opportunity with them hav-
ing, and other students not having, access and found this to be
morally unacceptable. However, Sattler et al.’s (2013a) finding
could also point to the experience of a “social norm,” following
from the prevalence of use that influences the judgment of moral
acceptability.
In a survey, Hotze et al. (2011) presented 633 US American
general practitioners with two statements related to this topic:
a slight majority agreed that society should prevent economic
advantages turning into biological advantages (57%), and that
everyone should have equal access to medical enhancers (55%).
Scheske and Schnall (2012) showed that the use of PCE sub-
stances is perceived as more wrong if not everybody can
afford them, compared to situations in which everybody can.
Fitz et al. (2013) investigated fairness by using the contrastive
vignette technique online. Their 4011 respondents, recruited via
Amazon’s Mechanical Turk, were randomly assigned to one of
22 different vignettes that described the use of PCE diverg-
ing in terms of alleged safety, societal and peer pressure, fair-
ness and authenticity. Respondents saw it as less fair if a stu-
dent obtained an enhancer with the help of money given by
his parents rather than with money earned by own work.
The 185 US American respondents in Sabini and Monterosso’s
(2005) study endorsed the so-called “interaction view” (p. 91):
their judgments of fairness depended on the group that was
affected by the drug. Although their fairness ratings of PCE
use were always close to or lower than the midpoint of the
scale—thus generally regarding it as rather unfair—respondents
believed the use by the worst performing 10% of students
to be fairer than the use by everybody or the top 10%. The
“interaction view” corresponds to what John Rawls (1971,
1985) calls the “difference principle”: inequality is acceptable
only if the current situation for those least advantaged is
improved.
A survey amongst 1026 German students demonstrated that
27% of the respondents approved the use of PCE by worse
performing classmates, while 57% approved the use for elderly
with declining cognitive performance (Schildmann et al., 2013).
Correspondingly, over a quarter of the respondents of another
study among German students reported that classmates with
low academic performance should be allowed to use PCE, while
50% indicated that the use of PCE by cognitively impaired
elderly should be allowed (Franke et al., 2012a). The percent-
age of respondents who endorsed the use of PCE by classmates
with low academic performance was higher among PCE users
than nonusers. It is clear that although the interaction view is
endorsed, previous performance is of less influence on judgments
of fairness of the use of PCE than age. However, this is perhaps
because the samples are both young students who are in com-
petition with other young students, so that age and performance
variables could be said to be confounded in the sample. Future
studies need to investigate the attitudes of young students in com-
petition with elderly students, and compare elderly students with
elderly non-students, so that attitudes toward these factors could
be separated. Sabini and Monterosso (2005) explain the interac-
tion view by arguing that a substance that would affect the worst
performing 10% only can better be seen as a normalizer instead
of an enhancer, suggesting that in this case it might be closer to a
treatment than to an enhancement. If this explanation is correct,
it would seem that both the acceptance of side effects as well as
the acceptance of a certain unequal distribution is greater in the
case of a treatment compared to enhancement.
In general, healthcare providers, students, and parents seem to
agree that an unequal distribution of PCE is unfair, if the unequal
distribution is related to factors that are changeable, such as
wealth. If the unequal distribution exists due to biological disposi-
tions, such as having a low attention span, an unequal distribution
is seen as less relevant to moral judgments. This is related to the
distinction between treatment and enhancement, in which the
former is generally believed to be seen as more acceptable (Parens,
1998; Daniels, 2000; Hyman, 2011). Users find it more acceptable
than nonusers that fellow students with low academic perfor-
mance use PCE, but research investigating the reasons for these
diverging views of users and nonusers is still lacking.
HONESTY
Honesty relates to the question of whether the use of PCE might
give a user an unfair advantage over people who do not use PCE,
and thus might need to exert more effort to achieve the same
result. Scheske and Schnall (2012) refer to honesty as competitive
Frontiers in Systems Neuroscience www.frontiersin.org April 2014 | Volume 8 | Article 53 | 9
Schelle et al. Attitudes toward pharmacological cognitive enhancement
fairness and Bostrom and Sandberg (2009) discuss it in relation
to cheating. Using an example and taking a normative stance,
Bostrom and Sandberg (2009) describe how goals and rules define
whether an act qualifies as cheating: if the primary goal of school-
ing is acquiring knowledge, PCE might be legitimate. In the case
of a competition for grades or admission, however, PCE could
be seen as cheating if it were against the rules or if access were
unequally distributed.
Quantitative accounts of the public’s opinion on honesty
related to PCE use can be found in several studies. Students
of a highly competitive UK university deemed the competitive
advantage PCE can give as one of the most important con-
cerns regarding its use: an advantage due to PCE use was found
most morally wrong when no other competitors were taking the
substance, relating competitive to distributive fairness and peer
pressure (Scheske and Schnall, 2012). Moreover, an online survey
by Bossaer et al. (2013) demonstrated that 60% of the 372 student
respondents agreed that PCE provides users with an unfair advan-
tage over other students. An almost identical amount of just over
half of the respondents (56%) believed that PCE use for study
purposes could be seen as academic dishonesty. In a large-scale
online survey, with respectively 5882 and 3486 participants in the
first and second wave, (Dubljevic´ et al., 2013) found that German
students deem the use of PCE with the intention to increase study
performance to be morally less acceptable than traditional forms
of academic misconduct, such as cheating in exams, fabrication,
or plagiarism. Schildmann et al. (2013) reported that half of the
respondents of their questionnaire study thought the use of PCE
by others was unfair, another quarter was unsure of their thoughts
about the statement, and only a quarter “rather” or “absolutely”
agreed that the use of PCE by others was fair. Over half of the
respondents in Franke et al. (2012a) indicated in a questionnaire
that they found PCE fair “under no circumstances” or “proba-
bly not.” This percentage was higher among females and among
nonusers. Although exact percentages are not provided, Sweeney
(2010) also discusses a survey amongst 100 students in which
nonusers felt more troubled than users by academic advantages
obtained by PCE. This difference between users and nonusers was
also found in the online survey by Ott and Biller-Andorno (2013).
They show that a little over 40% of nonusers agree that with using
PCE, one would be betraying others who do not use PCE, while
less than 20% of users agree to this statement. An online study
with 1200 male US American student participants revealed that
the misuse of performance enhancement substances in the sport-
ing domain received a higher rating on a scale that measured the
degree of cheating than the use of PCE in academia (Dodge et al.,
2012).
As described above, Fitz et al. (2013) showed that when obtain-
ing PCE takes less effort, it is seen as more unfair. This was
reflected in reduced fairness ratings in a scenario in which one
individual could use PCE and another could not. The effort
needed to obtain PCE was manipulated, as well as a second vari-
able, that of the effect of the PCE as either reducing the effort
needed to study or increasing the number of hours that one could
study for. The combination of diminished effort in obtainment
and reduced study effort produced the lowest ratings of fair-
ness. Thus, any variation of the description that would result in a
reduction of effort for the user of PCE in comparison to a nonuser
resulted in respondents judging PCE as less fair.
Qualitative studies provide a more elaborate but also more
ambiguous perspective on honesty in relation to PCE. In an inter-
view study amongst 19 Australian students by Bell et al. (2013
also c.f. Partridge et al., 2013) fairness appeared at the top of the
list of concerns mentioned. More than half of the participants
described PCE as a form of cheating, while most of the others
explicitly reported that they did not find it unfair in compar-
ison to other available methods for performance improvement
(e.g., coffee). In contrast to coffee, focus group participants saw
PCE as a form of cheating similar to the use of steroids (Forlini
and Racine, 2012b). Also, participants showed dissent and inde-
cision about whether PCE use should be seen as cheating or not
(Forlini and Racine, 2012a). Each subgroup of students, parents,
and health care providers included some individuals who saw
PCE as an unfair shortcut, putting others at a disadvantage, but
also individuals who considered PCE a study tool like any other.
To summarize, a little over half of the public believes that the
use of PCE provides an unfair advantage to users, a situation that
is seen as cheating, especially in highly competitive environments.
Nonusers provide lower ratings of honesty than users in quantita-
tive studies. In general there seems to be dissent on whether PCE
qualifies as cheating or not. Qualitative studies give more insight
into the different perspectives on this question.
AUTHENTICITY
In the normative debate, critics of PCE argue that users, com-
pared with nonusers, of enhancement substances experience the
value of exerting effort on a task less. This makes activities less
meaningful and facilitates fewer experiences of self-development
(see Schermer, 2008, for an analysis of this argument). Part of
the debate therefore relates to authentic performance, for which
effort is seen as a necessary condition (e.g., President’s Council
on Bioethics, 2003). Goodman (2010) specifies that this is true
for what he calls process goods, for which the activity itself is seen
as central. For so-called outcome goods, however, for which the
result of an activity counts, effort is less relevant.
We can apply the distinction between process goods and
outcome goods to the list of 19 traits rated by 357 respon-
dents in an online study by Riis et al. (2008). For each trait
they had to rate their willingness to enhance it using pharma-
cological means, if they could. Outcome related traits, such as
memory, received higher scores on willingness-to-enhance than
more process related traits, such as mood and social comfort.
These higher ratings for what we deem outcome related traits
might be explained by respondents valuing the notion of effort.
Furthermore, respondents were less willing to enhance traits that
were rated as more fundamental to the self, such as kindness and
empathy.
Participants in the focus group study by Forlini and Racine
(2012a) explicitly related effort to judgments of the fairness of
PCE. Students, parents, and healthcare providers commented
on effort and authenticity. They displayed both positive (non-
problematizing) and negative (problematizing) views toward PCE
in relation to effort and authenticity in equal proportions, as can
be seen in the following examples. Participants of each target
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group (students, parents, and healthcare providers) noted that
even with the use of PCE, effort still had to be put in to complete
certain tasks. However, participants also discussed how enhance-
ment may compromise certain social and personal values that
shape an individual’s behavior. Also some of the student par-
ticipants in the interview study by Bell et al. (2013) described
PCE as a quick fix rather than a true reflection of an individ-
ual’s abilities, while other participants neither reported effort
nor authenticity as being corrupted by the use of PCE. Two
thirds of the student respondents in the survey by Schildmann
et al. (2013) agreed that performances done with PCE were
“less commendable than comparable performances that are done
without these substances” (p. 25). In addition, 63% of the 644
physicians who completed the survey by Hotze et al. (2011)
viewed PCE as a threat to the value of human achievement.
Moreover, an online survey by Banjo et al. (2010) showed that
the respondents, 212 physicians, ranked “PCE undermines the
values of personal effort” as the fourth most important rea-
son (of 13 presented) to feel uncomfortable about prescrib-
ing PCE to non-elderly people. However, an online survey
among 1729 Australian students showed that users of prescrip-
tion amphetamines had fewer concerns regarding the integrity of
authentic and moral actions than did nonusers (Mazanov et al.,
2013).
Finally, in their experimental vignette study Fitz et al. (2013)
found that respondents rated an individual’s performance as sig-
nificantly less authentic when PCE was used, compared to when it
was not used. However, this opinion did not completely transfer
to judgments of worthiness for a promotion when the character
would be assigned a new project in his job. Respondents judged
a PCE user as significantly more worthy when successful without
enhancement compared to with enhancement, but they also indi-
cated that people who succeeded with the help of PCE were more
worthy of promotion than people who did not use PCE and failed.
To summarize, in general people are more likely to enhance
outcome related traits than process related traits. However, in
direct discussions about effort and authenticity in relation to fair-
ness, individuals display divergent opinions on the importance of
these topics. The proportion of people who believe effort is dis-
counted and authenticity violated when using PCE is a little over
half of the respondents in most studies. This implies that little
less than half of the public is not that concerned about effort and
authenticity in relation to PCE. One reason that is given is that
effort still has to be invested to achieve certain goals, even when
PCE is used.
CONCLUSION
This review provides an overview of 40 studies on the public’s
opinion about PCE. Our main finding is that in groups outside
the normative academic debate several concerns about the use
of pharmacological substances for performance enhancement are
either raised or endorsed. These concerns that are discussed in
the current review of research on opinions about PCE widely
match the normative debate. These similarities between the pub-
lic’s opinion and the normative debate are also found in studies
on other ethical issues, for example the sex selection of embryos
(Banks et al., 2006) and life extension technologies (Partridge
et al., 2009). The findings we present are divided between three
concerns regarding PCE use which are common in both the
ethical and lay debate: medical safety, coercion, and fairness.
Several studies have shown that medical safety is regarded as
central by nonusers of PCE, and insecurity about it provides a
reason for them to refuse the use of PCE. Related to this concern
are findings that point toward a preference for natural over artifi-
cial enhancers. A similar preference can be seen for interventions
that might be closer to treatment than to enhancement. Users,
on the other hand, do not display these preferences and indicate
conflicting results on judgments of (subjective) health risks asso-
ciated with PCE. They are concerned about addiction, but do not
worry about other health risks, and deem PCE more often harm-
less than nonusers do. A more convergent view can be found on
the theme of coercion. Different subgroups agree that PCE should
be a matter of personal choice. They believe that decisions con-
cerning use are, in general, made voluntarily, although they can be
influenced by perceived social pressure or by competitive environ-
ments. It is shown that peer pressure is a complex phenomenon,
as students might not always be influenced by other people’s PCE
use itself, but only when these others achieve a higher perfor-
mance compared to their own. However, only a few studies have
investigated coercion to date and we call for future research to
fill this gap. Finally, we discussed fairness, divided into three sub-
themes: equality of opportunity, honesty, and authenticity. An
unequal distribution of PCE substances that might develop due
to changeable factors—such as wealth—is seen as unfair, while
an unequal distribution due to biological dispositions—such as a
low attention span—is seen as less relevant to judgments of fair-
ness. This might relate to a general finding that treatments are
seen as more acceptable than enhancements. The public’s opin-
ion on the subthemes of honesty and authenticity shows a more
complex pattern. Nonusers believe more often than users that the
use of PCE provides an unfair advantage, although in general
only half of the public raises concerns about this topic of hon-
esty and cheating. Several studies show that around the theme of
authenticity both problematizing and non-problematizing views
on PCE arise in equal proportions. While some respondents indi-
cate that “the work has still to be done” even when PCE is used,
others believe that PCE is a quick fix and undermines an authentic
performance.
One important distinction within the public can be found
between users and nonusers, who tend to differ in their perspec-
tives on the medical safety and subthemes of the fairness of PCE:
while users generally deem PCE to be safe and fair, nonusers
do not. These results imply that users are either more willing
to engage in PCE because of their positive attitude toward it,
or that they adopted their positive attitude as a result of per-
sonal usage. In either case, the differences in users’ and nonusers’
attitudes toward PCE might be driven by cognitive biases. It is
possible, for example, that nonusers display a more negative view
toward PCE because they experience the so-called status quo
bias, which describes the irrational preference for an option only
because it preserves the current state of affairs (Kahneman and
Tversky, 2000). As currently PCE use is not seen as a common
way to improve cognitive performance, this bias might result
in the preference to not use PCE. This tendency, to use the
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status quo as a reference point, might explain why people pre-
fer interventions when they are seen as treatments as opposed to
enhancements (Bostrom and Ord, 2006). It is also possible, how-
ever, that users adopt a more positive view toward PCE in order
to reduce their cognitive dissonance, the discomfort experienced
when one’s actions don’t reflect one’s beliefs (Festinger, 1957).
This would reflect a situation in which users adapt their attitudes
toward their PCE use, that is, their behavior. Future research is
called to examine in greater depth which biases might influence
people’s attitudes toward PCE and the causal direction explaining
the attitudes currently prevalent. Further, future research might
also reveal whether differences between users and nonusers also
hold for other concerns, such as coercion and authenticity for
which data on this distinction is currently lacking.
It is important to note that the current literature focuses
mostly on opinions of students, with only a few exceptions pro-
vided by studies on health care providers and the general public.
Furthermore, several studies were conducted with a non-random
sample of participants, or obtained a low response rate in the case
of random sampling. This might have biased the results. In addi-
tion, even the studies that were conducted with random sampling
of students at specific universities can create a biased population
overview in our review, because differences between colleges on
the use of PCE are found (e.g., McCabe et al., 2005). Furthermore,
future research should provide more insight into the opinions of
populations other than students, such as the general population
or more specifically people active in the workforce. This would
add to a more accurate picture of opinions of the general pop-
ulation and of potential users in those areas where use is to be
expected.
Moreover, future research is called for to reveal more fine-
grained differences in the public opinion for certain concerns. In
the current literature, different concerns can have the same name,
as is seen with fairness, while different names may also be used
for the same concern, as was described for equality of opportu-
nity. This makes it harder to draw precise conclusions on the state
of research on public attitudes toward PCE and to systematically
compare it with arguments from the normative debate. Although
more fine-grained studies are needed to reflect the depth of the
normative debate, it can be said that, thus far, concerns of the
public regarding the use of PCE reflect the main issues fiercely
debated in academia.
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